← Leaderboards
Christopher Craig Dvorak
University Of California, San Francisco
$1,385,756
Attributed
$4,250,094
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,658,881 · 4
By mechanism
U54$8,078,459 · 3
R24$3,580,422 · 1
Top collaborators
- Elie Haddad7 shared
- Jennifer Maxwell Puck4 shared
- Rebecca Marsh3 shared
- Troy R Torgerson3 shared
- Michael Wagner3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Elie Haddad$1,288,114
- Tracey J. Woodruff$21,216,565
- Youngho Seo$10,977,149
- Scott W Biggins$609,930
- Lyudmila Popova$5,221,407
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsGenotypeSevere Combined ImmunodeficiencyProspectiveGene TherapyNatural HistoryT-LymphocyteLate EffectsDiagnosisNeonatal ScreeningProtocols DocumentationB-LymphocytesHematopoietic Cell TransplantationDoseFreedomBiological MarkersConditioningGenesPatient-Focused OutcomesImmuneCaringLifeFutureCanada
Grant awards (16)
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$1,743,065
R24 · FY2025 · AI · contact PI
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$21,475
R24 · FY2025 · AI · contact PI
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$1,815,882
R24 · FY2024 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,846,257
U54 · FY2023 · AI
Severe Combined Immune Deficiency: Prospective and Longitudinal Study of Genotypes, Management and Outcomes$93,335
U54 · FY2023 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,846,257
U54 · FY2022 · AI
Primary Immune Deficiency Treatment Consortium$1,846,474
U54 · FY2021 · AI
Severe Combined Immune Deficiency: Prospective and Longitudinal Study of Genotypes, Management and Outcomes$74,623
U54 · FY2021 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,869,799
U54 · FY2020 · AI
Severe Combined Immune Deficiency: Prospective and Longitudinal Study of Genotypes, Management and Outcomes$84,785
U54 · FY2020 · AI · contact PI
Severe Combined Immune Deficiency: Prospective and Longitudinal Study of Genotypes, Management and Outcomes$126,767
U54 · FY2019 · AI · contact PI
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders$61,344
U54 · FY2018 · AI · contact PI
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders$60,539
U54 · FY2017 · AI · contact PI
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders$58,455
U54 · FY2016 · AI · contact PI
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders$58,455
U54 · FY2015 · AI · contact PI
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders$51,369
U54 · FY2014 · AI · contact PI